Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.
Latest Ratings for CLMT
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Nov 2021Wolfe ResearchUpgradesPeer PerformOutperform Nov 2021Cowen & Co.UpgradesMarket PerformOutperform